Design, synthesis and molecular docking of novel substituted azepines as inhibitors of PI3K/Akt/TSC2/mTOR signaling pathway in colorectal carcinoma.
Humans
Proto-Oncogene Proteins c-akt
/ metabolism
Sirolimus
/ pharmacology
Phosphatidylinositol 3-Kinases
/ metabolism
Molecular Docking Simulation
TOR Serine-Threonine Kinases
/ metabolism
Caco-2 Cells
Tuberous Sclerosis
Azepines
/ chemistry
Signal Transduction
Colorectal Neoplasms
/ metabolism
Cell Proliferation
Cell Line, Tumor
Apoptosis
Azepines
Colorectal cancer
Docking study
Sonication
Journal
Bioorganic chemistry
ISSN: 1090-2120
Titre abrégé: Bioorg Chem
Pays: United States
ID NLM: 1303703
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
18
08
2022
revised:
29
09
2022
accepted:
21
11
2022
pubmed:
10
12
2022
medline:
21
1
2023
entrez:
9
12
2022
Statut:
ppublish
Résumé
A series of novel substituted azepines (2-7) was synthesized using both traditional and ultrasonic techniques. The efficiency of the reaction rate and yield was improved by sonication technique. We identified the newly synthesized compounds based on their melting points, elemental analyses, and spectral data. Human cancers are regulated mainly by the phosphatidylinositol 3-kinase/protein kinases B (PI3K/Akt) pathway, and its abnormal activation is linked to carcinogenesis, and angiogenesis. Using in-silico studies, we evaluated the ability of all the novel substituted diazepines and oxazepines to prevent cancer growth and metastasis by targeting the PI3K/Akt signaling pathway. Based on our findings, compounds 4a and 7a were chosen for in-vitro testing as they ranked via molecular docking the highest binding energies of -10.9, -10.3, -10.6, and -10.4 kcal/mol respectively. Compounds 4a and 7a displayed significant cytotoxicity on Caco-2 colorectal cancer cells with IC
Identifiants
pubmed: 36493622
pii: S0045-2068(22)00705-2
doi: 10.1016/j.bioorg.2022.106299
pii:
doi:
Substances chimiques
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Sirolimus
W36ZG6FT64
Phosphatidylinositol 3-Kinases
EC 2.7.1.-
TOR Serine-Threonine Kinases
EC 2.7.11.1
Azepines
0
MTOR protein, human
EC 2.7.1.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
106299Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.